TY - JOUR
T1 - Genetic variation of at-hook transcription factor (Akna) Rs3748178 is associated with the relapse of graves' disease
AU - Yanti, Dwi
AU - Suryandari, Dwi Anita
AU - Eliana, Fatimah
AU - Yunaini, Luluk
AU - Amir, Trisia Lusiana
N1 - Publisher Copyright:
© 2009-2019, JGPT.
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Objective: As many as 30-60% of patients with Graves' disease (GD) have relapsed after antithyroid withdrawal, which may be caused by genetic variation of susceptibility factors. This study aimed to analyze the genetic variation of AT-hook transcription factor AKNA rs3748178 and its association with relapse in Graves' disease patients. Methods: This research was a case-control study examining 60 DNA samples of GD patients, who were equally allocated into relapse and remission groups. Genetic variation was analyzed with PCR-RFLP. Fisher's exact test was used for statistical analysis and a p-value less than 0.05 was considered significant. Results: The proportion of patients who experienced a relapse with homozygote wild type (n= 27, 90%) was significantly higher (p= 0.015) compared to the heterozygote and homozygote mutant (n=3, 10%). Graves' disease patients with GG genotype were more likely to have a relapse (OR 6.00, 95% CI 1.48-24.3, p= 0.015). The proportion of patients who experienced a relapse with G allotype (95%) was significantly higher (p= 0.004) compared to A allotype (5%). Graves' disease patients with G allotype were more likely to have a relapse (OR 6.33, 95% CI 1.73-23.2, p= 0.004). Conclusions: Genetic variation of AT-hook transcription factor AKNA rs3748178 is associated with relapse in GD patients.
AB - Objective: As many as 30-60% of patients with Graves' disease (GD) have relapsed after antithyroid withdrawal, which may be caused by genetic variation of susceptibility factors. This study aimed to analyze the genetic variation of AT-hook transcription factor AKNA rs3748178 and its association with relapse in Graves' disease patients. Methods: This research was a case-control study examining 60 DNA samples of GD patients, who were equally allocated into relapse and remission groups. Genetic variation was analyzed with PCR-RFLP. Fisher's exact test was used for statistical analysis and a p-value less than 0.05 was considered significant. Results: The proportion of patients who experienced a relapse with homozygote wild type (n= 27, 90%) was significantly higher (p= 0.015) compared to the heterozygote and homozygote mutant (n=3, 10%). Graves' disease patients with GG genotype were more likely to have a relapse (OR 6.00, 95% CI 1.48-24.3, p= 0.015). The proportion of patients who experienced a relapse with G allotype (95%) was significantly higher (p= 0.004) compared to A allotype (5%). Graves' disease patients with G allotype were more likely to have a relapse (OR 6.33, 95% CI 1.73-23.2, p= 0.004). Conclusions: Genetic variation of AT-hook transcription factor AKNA rs3748178 is associated with relapse in GD patients.
KW - Genetic variation
KW - Graves' disease
KW - Recurrence
UR - http://www.scopus.com/inward/record.url?scp=85077750737&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:85077750737
SN - 0975-8542
VL - 11
SP - 295
EP - 300
JO - Journal of Global Pharma Technology
JF - Journal of Global Pharma Technology
IS - 8
ER -